{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:20:23Z","timestamp":1786980023310,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-022-04202-0","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T03:10:54Z","timestamp":1667790654000},"page":"2931-2937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimens"],"prefix":"10.1007","volume":"40","author":[{"given":"Alberto","family":"Martini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3087-3518","authenticated-orcid":false,"given":"Alae","family":"Touzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Beauval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Gasmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Thoulouzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Gauth\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Olivier","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Villers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the CC-AFU, Cancerology Committee of the Association Fran\u00e7aise d\u2019Urologie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"issue":"3","key":"4202_CR1","first-page":"125","volume":"50","author":"DF Gleason","year":"1966","unstructured":"Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50(3):125\u2013128","journal-title":"Cancer Chemother Rep"},{"issue":"21","key":"4202_CR2","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2008.20.4669","volume":"27","author":"JR Stark","year":"2009","unstructured":"Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27(21):3459\u20133464","journal-title":"J Clin Oncol"},{"issue":"5","key":"4202_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0090-4295(00)00753-6","volume":"56","author":"TY Chan","year":"2000","unstructured":"Chan TY, Partin AW, Walsh PC, Epstein JI (2000) Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56(5):823\u2013827","journal-title":"Urology"},{"issue":"6","key":"4202_CR4","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.juro.2009.08.026","volume":"182","author":"JL Wright","year":"2009","unstructured":"Wright JL, Salinas CA, Lin DW et al (2009) Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 182(6):2702\u20132707","journal-title":"J Urol"},{"issue":"2","key":"4202_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB et al (2016) International society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244\u201352","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4202_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bju.13478","volume":"118","author":"RC van den Bergh","year":"2016","unstructured":"van den Bergh RC, van der Kwast TH, de Jong J et al (2016) Validation of the novel international society of urological pathology 2014 five-tier Gleason grade grouping: biochemical recurrence rates for 3+5 disease may be overestimated. BJU Int 118(4):502\u2013505","journal-title":"BJU Int"},{"issue":"7","key":"4202_CR7","doi-asserted-by":"publisher","first-page":"461.e7","DOI":"10.1016\/j.urolonc.2017.02.012","volume":"35","author":"G Gandaglia","year":"2017","unstructured":"Gandaglia G, Karnes RJ, Sivaraman A et al (2017) Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. Urol Oncol 35(7):461.e7-461.e14","journal-title":"Urol Oncol"},{"issue":"1","key":"4202_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41379-020-0625-x","volume":"34","author":"E Hollemans","year":"2021","unstructured":"Hollemans E, Verhoef EI, Bangma CH et al (2021) Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Mod Pathol 34(1):184\u2013193","journal-title":"Mod Pathol"},{"issue":"5","key":"4202_CR9","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ejso.2020.12.014","volume":"47","author":"K Mori","year":"2021","unstructured":"Mori K, Sharma V, Comperat EM et al (2021) Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. Eur J Surg Oncol 47(5):1172\u20131178","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"4202_CR10","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.juro.2016.05.105","volume":"196","author":"N Harding-Jackson","year":"2016","unstructured":"Harding-Jackson N, Kryvenko ON, Whittington EE et al (2016) Outcome of Gleason 3 + 5 = 8 prostate cancer diagnosed on needle biopsy: prognostic comparison with Gleason 4 + 4 = 8. J Urol 196(4):1076\u20131081","journal-title":"J Urol"},{"issue":"1","key":"4202_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/bju.13239","volume":"118","author":"BA Mahal","year":"2016","unstructured":"Mahal BA, Muralidhar V, Chen YW et al (2016) Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int 118(1):95\u2013101","journal-title":"BJU Int"},{"issue":"6","key":"4202_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.eururo.2015.08.054","volume":"69","author":"MA Huynh","year":"2016","unstructured":"Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D\u2019Amico AV (2016) Gleason score 3 + 5 or 5 + 3 versus 4 + 4 prostate cancer: the risk of death. Eur Urol 69(6):976\u2013979","journal-title":"Eur Urol"},{"issue":"4","key":"4202_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s12253-017-0331-2","volume":"24","author":"TC Lu","year":"2018","unstructured":"Lu TC, Moretti K, Beckmann K, Cohen P, O\u2019Callaghan M (2018) ISUP group 4 - a homogenous group of prostate cancers? Pathol Oncol Res 24(4):921\u2013925","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"4202_CR14","doi-asserted-by":"publisher","first-page":"71 e11\u201371.e7.1E","DOI":"10.1016\/j.urolonc.2014.07.010","volume":"33","author":"CG Rusthoven","year":"2015","unstructured":"Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD (2015) Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 33(2):71 e11-71.e7.1E19","journal-title":"Urol Oncol."},{"key":"4202_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.humpath.2019.11.002","volume":"97","author":"ON Kryvenko","year":"2020","unstructured":"Kryvenko ON, Williamson SR, Schwartz LE, Epstein JI (2020) Gleason score 5 + 3 = 8 (grade group 4) prostate cancer-a rare occurrence with contemporary grading. Hum Pathol 97:40\u201351","journal-title":"Hum Pathol"},{"issue":"1","key":"4202_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bju.14740","volume":"124","author":"A Martini","year":"2019","unstructured":"Martini A, Wang J, Brown NM et al (2019) A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome. BJU Int 124(1):155\u2013162","journal-title":"BJU Int"},{"issue":"8","key":"4202_CR17","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","volume":"45","author":"TH van der Kwast","year":"2021","unstructured":"van der Kwast TH, van Leenders GJ, Berney DM et al (2021) ISUP consensus definition of cribriform pattern prostate cancer. Am J Surg Pathol 45(8):1118\u20131126","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"4202_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14722","volume":"75","author":"E Gun","year":"2021","unstructured":"Gun E, Ocal I (2021) Cribriform glands are associated with worse outcome than other pattern 4 subtypes: a study of prognostic and clinicopathological characteristics of prostate adenocarcinoma with an emphasis on grade groups. Int J Clin Pract 75(11):e14722","journal-title":"Int J Clin Pract"},{"issue":"6","key":"4202_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/modpathol.2016.49","volume":"29","author":"CF Kweldam","year":"2016","unstructured":"Kweldam CF, K\u00fcmmerlin IP, Nieboer D et al (2016) Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol 29(6):630\u2013636","journal-title":"Mod Pathol"},{"issue":"3","key":"4202_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/his.14590","volume":"80","author":"N Seyrek","year":"2022","unstructured":"Seyrek N, Hollemans E, Osanto S et al (2022) Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of grade group 2 prostate cancer patients. Histopathology 80(3):558\u2013565","journal-title":"Histopathology"},{"issue":"10","key":"4202_CR21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1097\/PAS.0000000000000691","volume":"40","author":"B Choy","year":"2016","unstructured":"Choy B, Pearce SM, Anderson BB et al (2016) Prognostic significance of percentage and architectural types of contemporary gleason pattern 4 prostate cancer in radical prostatectomy. Am J Surg Pathol 40(10):1400\u20131406","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"4202_CR22","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","volume":"50","author":"D Trudel","year":"2014","unstructured":"Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH (2014) Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer 50(9):1610\u20131616","journal-title":"Eur J Cancer"},{"key":"4202_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.humpath.2020.02.004","volume":"98","author":"MC Haffner","year":"2020","unstructured":"Haffner MC, Salles DC, Gao G, Epstein JI (2020) Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort. Hum Pathol 98:74\u201380","journal-title":"Hum Pathol"},{"issue":"12","key":"4202_CR24","doi-asserted-by":"publisher","first-page":"673.e9","DOI":"10.1016\/j.urolonc.2017.08.015","volume":"35","author":"BF Dinerman","year":"2017","unstructured":"Dinerman BF, Khani F, Golan R et al (2017) Population-based study of the incidence and survival for intraductal carcinoma of the prostate. Urol Oncol 35(12):673.e9-673.e14","journal-title":"Urol Oncol"},{"issue":"6","key":"4202_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/pros.22786","volume":"74","author":"K Kimura","year":"2014","unstructured":"Kimura K, Tsuzuki T, Kato M et al (2014) Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74(6):680\u2013687","journal-title":"Prostate"},{"issue":"8","key":"4202_CR26","first-page":"3990","volume":"11","author":"RB Shah","year":"2021","unstructured":"Shah RB, Cai Q, Aron M et al (2021) Diagnosis of \u201ccribriform\u201d prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Cancer Res 11(8):3990\u20134001","journal-title":"Am J Cancer Res"},{"issue":"7","key":"4202_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/gcc.20560","volume":"47","author":"O Bettendorf","year":"2008","unstructured":"Bettendorf O, Schmidt H, Staebler A et al (2008) Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer 47(7):565\u2013572","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"4202_CR28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1541-7786.MCR-18-0440","volume":"17","author":"H Elfandy","year":"2019","unstructured":"Elfandy H, Armenia J, Pederzoli F et al (2019) Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate. Mol Cancer Res 17(2):446\u2013456","journal-title":"Mol Cancer Res"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04202-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04202-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04202-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T09:07:59Z","timestamp":1669799279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04202-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04202-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"7 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted and approved ethically by the Prostate Group of the Oncology Section of the French Urological Association (AFU).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}